ArriVent BioPharma, Inc. Common Stock (AVBP) Stock Price
AVBPStock
$31.35+46.48%52W
Market Cap$1.55B
P/E—
PEG Ratio—
Div yield—
Beta1.41
AVBP Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)15.70%
Price vs S&P 500 (4W)-7.05%
VGM Score64.13
AVBP Earnings Surprise History
Q2 25-0.90est. -0.71
Q3 25-0.83est. -0.78
Q4 25-0.78est. -0.85
Q1 26-0.96est. -0.89
Q2 26-1.05est. -0.98
AVBP Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.32
4.32
4.32
4.33
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AVBPArriVent BioPharma, Inc. Common Stock | — | — | B | $31.35 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma is a clinical-stage biopharmaceutical company developing differentiated cancer therapeutics with an initial focus on solid tumors. The company's lead candidate, furmonertinib, is in clinical development, supported by a pipeline that includes next-generation antibody-drug conjugates designed to address unmet oncology needs.